Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver cancer patients, including two new studies investigating checkpoint inhibitors:
This study will investigate whether the immunotherapy nivolumab (Opdivo®) improves recurrence-free survival. Last year, the FDA granted accelerated approval of nivolumab for some patients with advanced liver cancer based on results of the CheckMate-040 trial. Read more.
This Phase 3 study will assess the safety and efficacy of the PD-L1 inhibitor durvalumab plus the CTLA-4 inhibitor tremelimumab compared to sorafenib in patients with no prior systemic therapy for unresectable HCC. Read more about this study in OncLive.
See previous coverage of earlier studies of all three of these potential therapies for liver cancer.
For more information about these featured studies at Providence Cancer Institute, or to enroll a patient, call our Clinical Research office at 503-215-2614.
See more studies for patients with liver cancer
Providence Cancer Institute currently has six studies open to patients with hepatocellular cancer and more than 120 studies open in all cancer types.
New research studies are added frequently. When searching for studies, be sure to check studies open to multiple tumor types in addition to specific tumor-type listings.
Providence Liver Cancer Clinic – a team approach
Providence Liver Cancer Clinic, with locations on Portland's east and west side, offers comprehensive, multidisciplinary care for people with liver cancer. Our team of liver surgeons, interventional radiologists, gastroenterologists, medical oncologists, radiation oncologists and oncology nurse navigators meets weekly to review individual patients’ cases and to determine the best approaches to treatment and care.
About the AuthorMore Content by Providence News Team